The etonogestrel subdermal contraceptive implant (EI), NexplanonⓇ, is a sterile 4 cm × 2 mm single rod that is implanted subdermally in a pregnancy-capable patient’s upper arm and can provide up to 3–5 years of continuous highly effective contraception. NexplanonⓇ prevents pregnancies primarily by inhibiting ovulation and secondarily by increasing cervical mucus viscosity and causing alterations in the endometrium. The most common side effect is changes in menstrual bleeding patterns. NexplanonⓇ (FDA-approved 2011) replaced the original etonogestrel subdermal contraceptive implant, ImplanonⓇ (FDA-approved 2006), due to cases of incorrect insertions with the ImplanonⓇ applicator device.